StreptAnova® a vaccine invented by two Memphis doctors that is designed to prevent group A streptococcal (GAS) infections, will be used in a Phase 1 clinical trial to be conducted in Canada, according to a report from Business Wire.
StreptAnova was invented by James B. Dale, MD, Chief of the Division of Infectious Disease, and Gene H. Stollerman, MD, Endowed Professor in Medicine at the University of Tennessee Health Science Center, and Research Scientist at the Memphis Veterans Affairs Medical Center.
The main objective of the trial is to demonstrate that the novel vaccine is safe and well tolerated in humans. The trial will be conducted at the Canadian Center for Vaccinology in Halifax, Nova Scotia.
Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a national Centre of Excellence for Commercialization and Research (CECR) located at the University of Saskatchewan and Memphis-based Vaxent announced the initiation of the clinical trial.
StreptAnova is being commercialized jointly by PREVENT and Vaxent, a company founded by Dr. Dale. StreptAnova is composed of four recombinant proteins containing protective peptides from 30 streptococcal serotypes that account for the vast majority of infections in North America and Europe.